Propanc Biopharma Stock Performance
| PPCB Stock | USD 8.89 6.13 222.10% |
Propanc Biopharma holds a performance score of 8 on a scale of zero to a hundred. The company holds a Beta of -7.3, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Propanc Biopharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Propanc Biopharma is expected to outperform it. Use Propanc Biopharma expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to analyze future returns on Propanc Biopharma.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Propanc Biopharma are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental indicators, Propanc Biopharma sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2255.00 |
Propanc |
Propanc Biopharma Relative Risk vs. Return Landscape
If you would invest 1,800 in Propanc Biopharma on November 18, 2024 and sell it today you would lose (911.00) from holding Propanc Biopharma or give up 50.61% of portfolio value over 90 days. Propanc Biopharma is currently generating 4.4128% in daily expected returns and assumes 39.5604% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Propanc, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Propanc Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Propanc Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Propanc Biopharma, and traders can use it to determine the average amount a Propanc Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1115
| Best Portfolio | Best Equity | PPCB | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 39.56 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.41 actual daily | 88 88% of assets have lower returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Propanc Biopharma is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Propanc Biopharma by adding it to a well-diversified portfolio.
Propanc Biopharma Fundamentals Growth
Propanc Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Propanc Biopharma, and Propanc Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Propanc Pink Sheet performance.
| Return On Asset | -13.07 | |||
| Current Valuation | 1.53 M | |||
| Shares Outstanding | 1.76 B | |||
| Price To Earning | (0.04) X | |||
| EBITDA | (2.14 M) | |||
| Cash And Equivalents | 4.07 K | |||
| Total Debt | 1.1 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.44 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 81.65 K | |||
About Propanc Biopharma Performance
By analyzing Propanc Biopharma's fundamental ratios, stakeholders can gain valuable insights into Propanc Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Propanc Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Propanc Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about Propanc Biopharma performance evaluation
Checking the ongoing alerts about Propanc Biopharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Propanc Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Propanc Biopharma is way too risky over 90 days horizon | |
| Propanc Biopharma appears to be risky and price may revert if volatility continues | |
| Propanc Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (2.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Propanc Biopharma currently holds about 4.07 K in cash with (1.44 M) of positive cash flow from operations. |
- Analyzing Propanc Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Propanc Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Propanc Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Propanc Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Propanc Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Propanc Biopharma's pink sheet. These opinions can provide insight into Propanc Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Propanc Pink Sheet analysis
When running Propanc Biopharma's price analysis, check to measure Propanc Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Propanc Biopharma is operating at the current time. Most of Propanc Biopharma's value examination focuses on studying past and present price action to predict the probability of Propanc Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Propanc Biopharma's price. Additionally, you may evaluate how the addition of Propanc Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |